文献速递技术与安全PETCT

黑色素瘤伊匹木单抗免疫治疗中的免疫介导性疾病:FDG PET-CT 表现

Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
PubMed 文献 · Acad Radiol · 2016-11-04

本文为回顾性病例系列研究,回顾接受伊匹木单抗免疫调节治疗的黑色素瘤患者的 F-18 FDG PET-CT 表现,筛选出 4 例出现免疫介导副作用的患者,包括免疫介导性胰腺炎、垂体炎、甲状腺炎和结肠炎所致异常 FDG 摄取增高;作者强调判读者需将免疫介导副作用的异常 FDG 摄取与高代谢恶性病灶相识别和区分。

要点

  • 伊匹木单抗治疗黑色素瘤患者中,FDG PET-CT 可检出免疫介导性胰腺炎、垂体炎、甲状腺炎和结肠炎的异常 FDG 摄取增高。
  • 判读时应将免疫介导副作用所致异常 FDG 摄取与高代谢恶性病灶相识别和区分。

核心结论

  • F-18 FDG PET-CT 可在接受伊匹木单抗免疫调节治疗的黑色素瘤患者中检出多种免疫介导副作用。
  • 判读者在使用 F-18 FDG PET-CT 监测伊匹木单抗对黑色素瘤病灶的疗效时,识别并区分免疫介导副作用所致异常 FDG 摄取与高代谢恶性病灶至关重要。

研究设计与样本

  • 回顾性病例系列研究,纳入诊断为黑色素瘤并接受伊匹木单抗免疫调节治疗的患者。
  • 回顾 F-18 FDG PET-CT 表现,筛选出现免疫介导副作用的患者,并结合临床病程记录、实验室检查结果及其他影像检查结果进行分析。

关键影像表现/征象

  • 免疫介导副作用表现为异常 FDG 摄取增高,包括免疫介导性胰腺炎和垂体炎,以及既往已报道的免疫介导性甲状腺炎和结肠炎。

临床应用与阅片要点

  • 在使用 F-18 FDG PET-CT 监测伊匹木单抗对黑色素瘤病灶的疗效时,判读者需识别并区分免疫介导副作用所致异常 FDG 摄取与高代谢恶性病灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: The purposes of this study were to provide a case-based overview of various immune-mediated side effects detected by 18F-Fluorodeoxyglucose (F-18 FDG) positron emission tomography-computed tomography (PET-CT) in the patients receiving ipilimumab immunotherapy for treatment of malignant melanoma, and discuss the importance of recognizing immune-mediated side effects in the use of F-18 FDG PET-CT for monitoring therapeutic effects of ipilimumab on metastatic melanoma.

MATERIALS AND METHODS: This is a retrospective case series study of the patients diagnosed with melanoma who were subjected to immunomodulating therapy with ipilimumab. F-18 FDG PET-CT findings were reviewed, and the patients with immune-mediated side effects were selected for further analysis, in conjunction with review of clinical progress notes, the results of laboratory tests, and findings of other imaging tests.

RESULTS: Four patients with immune-mediated side effects were identified among the patients being treated with ipilimumab and subjected to F-18 FDG PET-CT for monitoring therapeutic effects. These immune mediated side effects include new findings of abnormal increased FDG uptake associated with immune-mediated pancreatitis and hypophysitis, as well as immune-mediated thyroiditis and colitis reported previously.

CONCLUSIONS: Various immune-mediated side effects were detected by F-18 FDG PET-CT in the patients subjected to immunomodulating therapy with ipilimumab. It is essential for the interpreting provider to recognize and differentiate abnormal FDG uptake associated with immune-mediated side effects from hypermetabolic malignant lesions when using F-18 FDG PET-CT for monitoring therapeutic effects of ipilimumab on melanoma lesions.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wachsmann JW, Ganti R, Peng F, et al. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. Acad Radiol. 2016. PMID: 27818005. doi:10.1016/j.acra.2016.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。